Dr. John Sarantopoulos, M.D.
What this data tells you about Dr. Sarantopoulos
Dr. John Sarantopoulos is a medical oncology in San Antonio, TX, with 20 years in practice. Based on federal Medicare data, Dr. Sarantopoulos performed 14,065 Medicare services across 707 unique beneficiaries.
Between the years covered by Open Payments, Dr. Sarantopoulos received a total of $639,225 from 25 pharmaceutical and/or device companies across 736 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in medical oncology. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Sarantopoulos is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
Medicare Practice Summary
Medicare Utilization ↗Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Oxaliplatin chemotherapy injection | 4,430 | $0 | $0 |
| Pembrolizumab injection (Keytruda) | 3,600 | $43 | $160 |
| Anti-nausea injection (fosaprepitant) | 3,000 | $0 | $1 |
| Anti-nausea injection (ondansetron/Zofran) | 768 | $0 | $0 |
| Dexamethasone injection (steroid) | 689 | $0 | $0 |
| Injection, fluorouracil, 500 mg | 263 | $2 | $7 |
| Anti-nausea injection (Aloxi/palonosetron) | 210 | $1 | $6 |
| Office visit, established patient (30-39 min) | 208 | $97 | $312 |
| Injection, magnesium sulfate, per 500 mg | 160 | $1 | $2 |
| Injection of additional new drug or substance into vein | 155 | $12 | $46 |
| Administration of chemotherapy into vein, 1 hour or less | 118 | $99 | $384 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 93 | $22 | $87 |
| Administration of chemotherapy into vein, each additional hour | 44 | $22 | $83 |
| Telephone medical discussion with physician, 11-20 minutes | 44 | $64 | $221 |
| Office visit, established patient, complex (40-54 min) | 36 | $140 | $438 |
| Drug injection, under skin or into muscle | 32 | $11 | $41 |
| Telephone medical discussion with physician, 21-30 minutes | 31 | $99 | $312 |
| Administration of additional new drug or substance into vein, 1 hour or less | 30 | $50 | $192 |
| Injection, diphenhydramine hcl, up to 50 mg | 30 | $1 | $3 |
| Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l | 27 | $127 | $470 |
| Infusion into a vein for hydration, each additional hour | 22 | $10 | $38 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 22 | $16 | $62 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 20 | $49 | $196 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 19 | $56 | $214 |
| Infusion, normal saline solution , 1000 cc | 14 | $2 | $8 |
Industry Payment Transparency
Open Payments through 2024 ↗Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
Payments by company (2024)
Associated products mentioned in payments ›
The majority of payments (98%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in medical oncology and does not inherently indicate bias, but patients may wish to be aware. Total industry engagement is in the top 3% for medical oncology in TX.
Geographic Context
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Sarantopoulos is a mixed practice specialist, with moderate Medicare volume, and high industry engagement (speaking/promotional, top 3%), with 20 years of practice experience.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Sarantopoulos experienced with oxaliplatin chemotherapy injection?
Does Dr. Sarantopoulos receive payments from pharmaceutical companies?
How do Dr. Sarantopoulos's costs compare to other medical oncologys in San Antonio?
What does Data Coverage mean?
Is this data up to date?
Explore related providers
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology